MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
Ivacaftor
CAS No. : 873054-44-5
MCE 国际站:Ivacaftor
产品活性:Ivacaftor (VX-770) 是一种有效可口服的 CFTR 增效剂,靶向G551D-CFTR和F508del-CFTR的EC50分别为100 nM 和 25 nM。
研究领域:Membrane Transporter/Ion Channel | Autophagy
In Vitro: Ivacaftor (10 µM) increases the PC secretion activity by 3-fold for ABCB4-G535D, 13.7-fold for ABCB4-G536R, 6.7-fold for ABCB4-S1076C, 9.4-fold for ABCB4-S1176L, and 5.7-fold for ABCB4-G1178S. Ivacaftor corrects the functional defect of ABCB4 mutants. Ivacaftor (10 μM) significantly increases CFTR activity in W1282X-expressing cells compared to R1162X CFTR cells. Ivacaftor shows no significant activity against 160 targets tested including the GABAA benzodiazepine receptor. Ivacaftor increases the chloride secretion with an EC50 of 0.236 ± 0.200 μM, a 10-fold shift in potency compared to the F508del HBEs. In recombinant cells, VX-770 increases CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation. VX-770 increases forskolin-stimulated IT in temperature-corrected F508del-FRT cells by appr 6-fold with an EC50 of 25 nM.
In Vivo: Ivacaftor (1-200 mg/kg, p.o.) exhibits good oral bioavailability in rat.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Membrane Transporter/Ion Channel Compound Library | FDA-Approved Drug Library | Autophagy Compound Library | Drug Repurposing Compound Library | Endocrinology Compound Library | Anti-COVID-19 Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Rare Diseases Drug Library | Children’s Drug Library | EMA-Approved Drug Library | Human Metabolite Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Cell Death Library | Bioactive Compound Library Max | Glibenclamide | Lumacaftor | Tezacaftor | CFTR(inh)-172 | Elexacaftor | Ataluren | Glucosamine | SRI-41315 | GlyH-101 | (R)-BPO-27 | Vanzacaftor | IOWH-032 | GLPG1837 | Nesolicaftor | 5,7,4'-Trimethoxyflavone | Bamocaftor | Cavosonstat | Galicaftor | NJH-2-057 | PPQ-102 | SRI-37240 | Icenticaftor | Navocaftor | Chromanol 293B | Olacaftor | Crinecerfont hydrochloride | Posenacaftor sodium | Astressin 2B TFA
热门产品线:重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。